New Delhi: The first real-world assessment of BBV152, a COVID-19 vaccine developed in India, known as COVAXIN in the country, suggests that two vaccine doses result in 50 percent effectiveness against symptomatic COVID-19.
London: Interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India and known as Covaxin, reports that two doses offer 77.8% protection against symptomatic COVID-19, finds Lancet study.
New Delhi/UNI: Travellers who have received both doses of Covaxin are now eligible for inbound travel to Hong Kong as the country has included the India-made COVID-19 vaccine into its list of approved vaccines.
London/IBNS: Britain on Monday said it would give approval to India's indigenous COVID-19 vaccine-Covaxin-and travellers inoculated with both the shots will not be required to quarantine, media reports said.
New Delhi/UNI: Ocugen Inc, Bharat Biotech's partner in the US and Canada for Covaxin, has submitted a request to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the Covid-19 jab for paediatric use.
New Delhi/IBNS: Covaxin did not take the longest to get the World Health Organization's (WHO) approval for Emergency Use Listing, according to Chief Scientist Dr Soumya Swaminathan.
New Delhi/IBNS: The World Health Organization (WHO) has given emergency use approval to Bharat Biotech's Covaxin, sources said Wednesday, clearing the way for the 'made-in-India' vaccine to get recognised by other nations and Indians inoculated with the shot would no longer need to self-quarantine or face restrictions when going abroad.
Muscat/IBNS: The Government of the Sultanate of Oman on Wednesday approved Indian-made Covaxin to the list of allowed COVID-19 vaccines for travel to the country without quarantine.
New Delhi/UNI: The process to include indigenously developed COVID-19 vaccine, Covaxin, in Emergency Use Listing (EUL) of World Health Organisation (WHO) is delayed by a week as the Technical Advisory Group of the UN body has sought "additional clarifications" from the vaccine manufacturer.
New Delhi/IBNS: An expert panel on Tuesday recommended Bharat Biotech's Covaxin to be administered on children between the ages of two and 18.
New Delhi/IBNS: The World Health Organisation (WHO) on Tuesday said it will announce its decision on clearance of India's indigenously developed Covaxin next week when the UN agency and an independent group of experts meet.
New Delhi/IBNS: The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the COVID vaccine developed in India by pharmaceutical company Bharat Biotech, media reports said.
New Delhi/IBNS: India would not buy Covid-19 vaccines from foreign producers Pfizer/BioNTech and Moderna as domestic production of the shots has increased manifold, Reuters reported citing sources.
New Delhi/IBNS: The World Health Organisation's emergency approval for indigenously made Covid-19 jab, Covaxin, can come by the end of September, said Dr VK Paul, chairman of the National Expert Committee on Vaccine Administration, according to media reports.
New Delhi/UNI/IBNS: India logged 25,404 new cases and 339 deaths due to the COVID-19 in the last 24 hours, the Union Health Ministry said Tuesday.